|
|
|
|
|
|
Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00093470 |
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone in preventing the recurrence of acute myeloid leukemia.
PURPOSE: This randomized phase III trial is studying how well tipifarnib works compared to observation alone in preventing cancer recurrence in patients with acute myeloid leukemia.
Condition | Intervention | Phase |
Leukemia Myelodysplastic Syndromes |
Drug: tipifarnib Procedure: observation |
Phase III |
MedlinePlus related topics: | Cancer Leukemia, Adult Acute Leukemia, Adult Chronic |
ChemIDplus related topics: | Tipifarnib |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control |
Official Title: | A Phase III Randomized Study Of Farnesyl Transferase Inhibitor R115777 In Acute Myeloid Leukemia (AML) Patients In Second Or Subsequent Remission Or In Remission After Primary Induction Failure |
Estimated Enrollment: | 139 |
Study Start Date: | August 2004 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm I: Experimental
Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Drug: tipifarnib
Given orally
|
Arm II: No Intervention
Patients undergo observation only.
|
Procedure: observation
No intervention
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to remission status (first complete remission [CR] vs > first CR) and prior treatment for the most current remission (consolidation therapy vs no therapy). Patients are randomized to 1 of 2 treatment arms.
PROJECTED ACCRUAL: A total of 139 patients (69-70 per treatment arm) will be accrued for this study within 3.5 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Morphologically confirmed acute myeloid leukemia (AML) of 1 of the following types:
In complete remission (CR) or molecular remission (MR) by blood counts and bone marrow studies* AND meets 1 of the following criteria:
In first CR after primary induction failure
Patients must meet 1 of the following criteria:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Show 211 Study Locations |
Eastern Cooperative Oncology Group |
National Cancer Institute (NCI) |
Study Chair: | Selina M. Luger, MD | University of Pennsylvania |
Investigator: | Jacob M. Rowe, MD | Rambam Health Care Campus |
Investigator: | Mark R. Litzow, MD | Mayo Clinic |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000387995, ECOG-E2902 |
First Received: | October 6, 2004 |
Last Updated: | October 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00093470 |
Health Authority: | Unspecified |
|
|
|
|
|
|